Johanna Roberts Sells 600 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $190.76, for a total transaction of $114,456.00. Following the transaction, the executive vice president now directly owns 60,488 shares in the company, valued at approximately $11,538,690.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Johanna Roberts also recently made the following trade(s):

• On Tuesday, September 3rd, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $206.22, for a total transaction of $123,732.00.
• On Tuesday, August 13th, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $175.98, for a total transaction of $105,588.00.

Penumbra Stock Down 0.1 %

Shares of NYSE:PEN opened at $194.73 on Friday. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $277.34. The company has a market capitalization of $7.55 billion, a PE ratio of 82.16, a price-to-earnings-growth ratio of 2.18 and a beta of 0.54. The business has a fifty day moving average price of $190.58 and a two-hundred day moving average price of $195.77. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.25 and a quick ratio of 3.77.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.08. Penumbra had a net margin of 1.26% and a return on equity of 8.39%. The company had revenue of $299.40 million for the quarter, compared to the consensus estimate of $298.24 million. During the same period in the previous year, the firm earned $0.43 EPS. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. Analysts forecast that Penumbra, Inc. will post 2.59 earnings per share for the current year.

Penumbra declared that its board has authorized a share buyback plan on Tuesday, August 13th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to repurchase up to 2.6% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

Institutional Investors Weigh In On Penumbra

Several large investors have recently modified their holdings of PEN. Allianz Asset Management GmbH grew its holdings in Penumbra by 9.7% during the fourth quarter. Allianz Asset Management GmbH now owns 7,182 shares of the company’s stock valued at $1,807,000 after purchasing an additional 637 shares during the period. KBC Group NV purchased a new position in shares of Penumbra during the 4th quarter valued at $175,000. The Manufacturers Life Insurance Company grew its stake in shares of Penumbra by 8.7% during the 4th quarter. The Manufacturers Life Insurance Company now owns 99,881 shares of the company’s stock worth $25,124,000 after acquiring an additional 8,029 shares during the period. Azimuth Capital Investment Management LLC increased its holdings in Penumbra by 22.3% in the 4th quarter. Azimuth Capital Investment Management LLC now owns 66,201 shares of the company’s stock worth $16,652,000 after acquiring an additional 12,088 shares during the last quarter. Finally, Braidwell LP increased its holdings in Penumbra by 133.7% in the 4th quarter. Braidwell LP now owns 222,792 shares of the company’s stock worth $56,041,000 after acquiring an additional 127,477 shares during the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on PEN shares. Robert W. Baird dropped their price target on Penumbra from $231.00 to $180.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 31st. Citigroup upped their target price on Penumbra from $178.00 to $200.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Royal Bank of Canada reduced their price target on shares of Penumbra from $289.00 to $205.00 and set an “outperform” rating for the company in a research report on Wednesday, July 31st. Truist Financial restated a “buy” rating and set a $200.00 price objective (down previously from $230.00) on shares of Penumbra in a report on Wednesday, July 31st. Finally, Leerink Partners began coverage on shares of Penumbra in a research note on Tuesday, September 3rd. They issued an “outperform” rating and a $263.00 price objective on the stock. Five analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $208.00.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.